Hyperthyroidism (primary)

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Hyperthyroidism (primary). / Nygaard, Birte.

In: Clinical Evidence (Online), Vol. 2010, 01.01.2010.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Nygaard, B 2010, 'Hyperthyroidism (primary)', Clinical Evidence (Online), vol. 2010.

APA

Nygaard, B. (2010). Hyperthyroidism (primary). Clinical Evidence (Online), 2010.

Vancouver

Nygaard B. Hyperthyroidism (primary). Clinical Evidence (Online). 2010 Jan 1;2010.

Author

Nygaard, Birte. / Hyperthyroidism (primary). In: Clinical Evidence (Online). 2010 ; Vol. 2010.

Bibtex

@article{dfe58d488fa848b7a69688f81b613741,
title = "Hyperthyroidism (primary)",
abstract = "Hyperthyroidism is characterised by high levels of serum thyroxine and triiodothyronine, and low levels of thyroid-stimulating hormone. The main causes of hyperthyroidism are Graves' disease, toxic multinodular goitre, and toxic adenoma. About 20 times more women than men have hyperthyroidism. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for primary hyperthyroidism? What are the effects of surgical treatments for primary hyperthyroidism? What are the effects of treatments for subclinical hyperthyroidism? We searched: Medline, Embase, The Cochrane Library, and other important databases up to February 2010 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).",
author = "Birte Nygaard",
year = "2010",
month = jan,
day = "1",
language = "English",
volume = "2010",
journal = "BMJ clinical evidence",
issn = "1752-8526",
publisher = "B M J Group",

}

RIS

TY - JOUR

T1 - Hyperthyroidism (primary)

AU - Nygaard, Birte

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Hyperthyroidism is characterised by high levels of serum thyroxine and triiodothyronine, and low levels of thyroid-stimulating hormone. The main causes of hyperthyroidism are Graves' disease, toxic multinodular goitre, and toxic adenoma. About 20 times more women than men have hyperthyroidism. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for primary hyperthyroidism? What are the effects of surgical treatments for primary hyperthyroidism? What are the effects of treatments for subclinical hyperthyroidism? We searched: Medline, Embase, The Cochrane Library, and other important databases up to February 2010 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

AB - Hyperthyroidism is characterised by high levels of serum thyroxine and triiodothyronine, and low levels of thyroid-stimulating hormone. The main causes of hyperthyroidism are Graves' disease, toxic multinodular goitre, and toxic adenoma. About 20 times more women than men have hyperthyroidism. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for primary hyperthyroidism? What are the effects of surgical treatments for primary hyperthyroidism? What are the effects of treatments for subclinical hyperthyroidism? We searched: Medline, Embase, The Cochrane Library, and other important databases up to February 2010 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

M3 - Journal article

VL - 2010

JO - BMJ clinical evidence

JF - BMJ clinical evidence

SN - 1752-8526

ER -

ID: 34146922